FDA Approves Cymbalta(R) For Maintenance Treatment Of Generalized Anxiety Disorder
The U.S. Food and Drug Administration has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, Eli Lilly and Company announced. The efficacy and safety of Cymbalta for the maintenance treatment of GAD were established in a double-blind, placebo-controlled trial. Patients with GAD who initially had responded to treatment with Cymbalta 60-120 mg/day during a 26-week open-label phase were randomly assigned to receive Cymbalta 60-120mg/day or placebo.
For the full story, Click Here
- FDA approves Gamunex for CIDP’s treatment
- Research: No effective treatment for OA
- FDA Approves ACTEMRA(R) (tocilizumab) For The Treatment Of Moderately To Severely Active Rheumatoid Arthritis
- FDA approves Talecris Biotherapeutics PROLASTIN-C
